New Delhi: Hours after the Drug Controller General of India (DCGI) authorized the emergency use authorisation of the Sputnik V COVID-19 vaccine on Monday (April 12, 2011), the Russian Direct Investment Fund (RDIF) introduced that it’s aiming to produce greater than 850 million doses per yr in India.
“Over 850 million doses of Sputnik V are going to be produced in India annually sufficient to vaccinate more than 425 million people around the world,” the RDIF CEO Kirill Dmitriev stated in a press assertion.
Dmitriev added, “The Russian vaccine has efficacy of 91.6% and provides full protection against severe cases of COVID-19 as demonstrated by the data published in one of the leading medical journals The Lancet.”
The RDIF additionally knowledgeable that India has change into the sixtieth nation to approve Sputnik VÂ and is essentially the most populated nation to register the Russian vaccine.Â
“Total population of 60 countries where Sputnik V is approved for use is 3 billion people or about 40% of the global population,” the RDIF acknowledged.
It has additionally been authorized in nations like Russia, Belarus, Argentina, Serbia, Algeria, Palestine, Venezuela, Paraguay, Hungary, UAE, Iran, Mexico, Lebanon, Myanmar, Pakistan, Sri Lanka and Iraq.
Sputnik V, notably, is without doubt one of the three coronavirus vaccines registered by India‘s regulatory authorities.
The vaccine has been registered in India below the emergency use authorization process primarily based on outcomes of scientific trials in Russia in addition to optimistic information of extra Phase III native scientific trials in India performed in partnership with Dr Reddy’s Laboratories.
In India, the RDIF has reached agreements with the pharmaceutical firms like Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech.
Â
